Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q96G03

UPID:
PGM2_HUMAN

ALTERNATIVE NAMES:
Glucose phosphomutase 2; Phosphodeoxyribomutase; Phosphoglucomutase-2

ALTERNATIVE UPACC:
Q96G03; B4E0G8; Q53FP5; Q5QTR0; Q9H0P9; Q9NV22

BACKGROUND:
The enzyme Phosphopentomutase, also recognized as Glucose phosphomutase 2, Phosphodeoxyribomutase, and Phosphoglucomutase-2, is pivotal in the biochemical landscape of cells. It efficiently catalyzes critical steps in the metabolism of nucleosides and glucose, including the conversion of ribose-1-phosphate and deoxyribose-1-phosphate to 5-phosphopentoses and the interconversion of glucose-1-phosphate to glucose-6-phosphate. Despite its lower catalytic efficiency in some reactions, its broad enzymatic capabilities underscore its biological significance.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Phosphopentomutase unveils potential pathways for therapeutic intervention. Given its central role in metabolic processes, targeting this enzyme could lead to innovative treatments for metabolic diseases, marking a significant leap forward in the realm of precision medicine.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.